Edmond DE Rothschild Holding S.A. reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 22.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,083 shares of the company's stock after selling 21,888 shares during the quarter. Edmond DE Rothschild Holding S.A.'s holdings in Moderna were worth $3,080,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new position in Moderna during the fourth quarter worth about $163,833,000. State Street Corp increased its holdings in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company's stock worth $1,125,899,000 after buying an additional 1,823,276 shares in the last quarter. Pictet Asset Management Holding SA raised its stake in shares of Moderna by 170.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock valued at $73,447,000 after acquiring an additional 1,113,455 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock worth $349,166,000 after acquiring an additional 906,114 shares in the last quarter. Finally, Amundi grew its position in Moderna by 79.8% during the 4th quarter. Amundi now owns 1,206,273 shares of the company's stock worth $52,075,000 after acquiring an additional 535,273 shares during the last quarter. 75.33% of the stock is owned by institutional investors.
Moderna Stock Performance
NASDAQ MRNA traded up $0.56 on Wednesday, reaching $27.72. The company had a trading volume of 11,792,223 shares, compared to its average volume of 6,943,608. The company's fifty day moving average is $34.43 and its 200-day moving average is $43.55. Moderna, Inc. has a 1-year low of $26.32 and a 1-year high of $170.47. The firm has a market capitalization of $10.72 billion, a price-to-earnings ratio of -2.99 and a beta of 1.86.
Analyst Ratings Changes
MRNA has been the topic of several research analyst reports. Leerink Partners decreased their target price on Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. UBS Group decreased their price objective on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. JPMorgan Chase & Co. reduced their target price on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Friday, March 21st. Citigroup assumed coverage on shares of Moderna in a report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target for the company. Finally, Evercore ISI set a $50.00 price objective on Moderna in a report on Friday, February 14th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $59.00.
Check Out Our Latest Report on Moderna
About Moderna
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
See Also
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
